M. Michelle Berrey, M.D., MPH.
Dr. Michelle Berrey is currently President, Research and Development, and Chief Medical Officer at Intercept Pharmaceuticals, committed to the development and commercialization of new medicines for non-viral liver diseases. She previously served as President and Chief Executive Officer at Chimerix. Prior to this she was Chief Medical Officer at Pharmasset where she played a critical role in the development of Sovaldi® (sofosbuvir), which established a transformational new treatment paradigm for patients with hepatitis C virus. Before joining Pharmasset, Dr. Berrey was Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline. Dr. Berrey received her M.D. from the Medical College of Georgia and a Master of Public Health from Emory University.